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Abstract
Background: Romiplostim is a peptibody analogue of thrombopoietin (TPO) which regulates platelet production.
This molecule consists of two main parts: Peptide sequences which like wild type TPO, mimics stimulation of TPO
receptor and IgG1Fc, (Peptide + Antibody = Peptibody). This drug is used in treatment of chronic Immune
Thrombocytopenic Purpura (ITP).
Methods: In this project E. coli bacteria were transformed by a construct harboring peptibody fusion gene. This
construct consisted of two repeated peptide sequences which have fused to Carboxyl group of IgG1Fc. Designed
construct in E. coli host resulted in protein expression in cytoplasm as inclusion body. The inclusion bodies were
separated, washed and after denaturation and solubilization, in the last stage the desired peptibodies were refolded
and purified. The resulting peptibodies were characterized by SDS-PAGE and Western immunoblotting. The bioactivity
were assessed in vivo using subcutaneous injection in mice.
Results: Results showed accurate molecules were produced and purified. Also, in vivo experiment showed significant
increment (more than two fold) of platelets compared to control group.
Conclusion: In this study laboratory scale production of recombinant romiplostim showed proper in-vivo bioactivity.
This new approach in expression and purification of this recently introduced thrombopoietin receptor agonist drug
may be followed by scale up of its production to response the chronic ITP patient’s demand.
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Background
Immune thrombocytopenic purpura (ITP) is considered
as an autoimmune disorder characterized by platelet defi-
ciency due to platelet destruction and/or insufficient pro-
duction. [1, 2]. Although the exact cause of ITP is not well
known, mediating mechanisms in the progress of
thrombocytopenia as anti-platelet antibodies and cellular
(T-cell) mediated mechanisms are proven [2]. According
to European studies, the incidence of ITP in adults is
estimated as 1.6 to 2.25 cases per 100,000 population per
year (platelet count ≤50 ×109 cells/L) [3, 4]. The first step
of ITP treatment includes administration of corticoste-
roids or intravenous immunoglobulin (IVIg). Patients who
do not respond, are candidate for splenectomy. Indeed,
25 % to 30 % of patients with chronic ITP do not respond
to initial treatment or splenectomy [2, 5].
First generation thrombopoietic agents were recom-
binant forms of human Thrombopoietin (TPO), like
PEG-MGDF [6]. TPO is the endogenous ligand for the
thrombopoiein receptor which is expressed on the sur-
face of platelets and megakaryocytes and involves in
stimulating thrombopoiesis [7, 8]. The expansion of
these agents did not continued because of neutralizing
auto-antibodies cross-reacting with endogenous TPO.
Therefore, recently introduced second-generation throm-
bopoiesis stimulating molecules, with no sequence hom-
ology to endogenous TPO, are used [7]. Romiplostim is
one of these new agents which has already completed
phase III trials in primary immune thrombocytopenia and
had taken FDA approved for treatment of ITP patients re-
sistant to corticosteroid therapy and speloectomy [1].
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Romiplostim is an Fc-peptide fusion protein, or peptibody.
It consists of 2 identical single-chain subunits, each con-
taining human IgG1 Fc domains linked covalently at the
C-terminus to a peptide that contains 2 thrombopoietin
(TPO) receptor (c-Mpl)–binding domains (4 binding sites
in total) [9, 10]. It prompts the transcriptional pathways
that stimulate the c-Mpl receptor, leading to improved
platelet production [11, 12]. In this study we have
constructed romiplostim recombinant plasmid in E coli,
expressed and analyzed it in the laboratory scale.
Methods
Cloning of romiplostim gene
Nucleotide sequence of Romiplostim was retrieved from
the US patent (6835809 B1) and the synthetic lyophilized
construct purchased from BIOMATIK Company. Four
microgram of lyophilized DNA was suspended in 40 μl
nuclease-free water (final concentration 100 ng/μl) and
2 μl of suspension was transformed into E. coli (DH5α)
according to InsTAclone PCR Cloning Kit (Thermo Sci-
entific). The mixture was plated on LB agar (+Amp) and
incubated overnight at 37 °C. Next day, some well sepa-
rated single colonies were selected and inoculated in LB
medium (+Amp) at 37 °C for overnight culture.
To confirm transformation, colony PCR with M13
primers were performed and the positive colonies’ plas-
mids were purified (GeneJET Plasmid Miniprep Kit,
Thermo Scientific) and digested with Hind III restriction
enzyme (Vivantis) overnight at 37 °C to confirm the
fragment insertion.
Subcloning of romiplostim gene in pET22b (+) expression
vector
The plasmid was purified and double digested with
BamHI/NdeI restriction enzymes (Vivantis) to retrieve
the subjected fragment. On the other hand, pET-22b(+)
was cleaved with same restriction enzymes. The Romi-
plostim fragment was ligated into the pET-22b(+) using
T4 DNA ligase (Fermentas), and the ligation mixture
was transformed to BL21 (DE3) E. coli. The positive
clones were selected based on the result of colony PCR
with T7 universal primers.
Expression of recombinant romiplostim
Expression of recombinant Romiplostim was done in LB
broth and optimized in different times (2, 4, 6 h and over-
night) with IPTG (1 mM) as inducer at 30 and 37 °C.
Five ml of media was inoculated by 500 μl of an over-
night fresh culture of expression host. Induction was
carried out when culture had reached to the O.D. of 0.5
at 600 nm. Zero, 2 h, 4 h, 6 h and overnight samples be-
sides overnight sample without IPTG and overnight
sample of BL21 (DE3) (without any plasmid) were cen-
trifuged in 4°c at 13000 rpm for 5 min. Pellets were re-
suspended in 5× SDS-PAGE sample buffer and water
boiled for 5 min. The analysis was performed by 12 %
SDS-PAGE electrophoresis followed by comassie brilliant
blue G-250 staining (Merck).
Western blot analysis
The separated proteins by 12 % SDS-PAGE were trans-
ferred into nitrocellulose for 1 h at 100 V, 350 mA using
wet Bio-Rad transfer system (Bio-Rad, Hercules, CA).
The membrane was blocked by 2 % BSA and 0.1 %
Tween 20 in 1× TBS buffer (pH 7.4) at 4 °C for over-
night. Then it was incubated in 1/2000 dilution of Affin-
pure Goat Anti-Human IgG Fcγ Fragment Specific
(Jackson) for 1 h at 37 °C. Then, it was washed 4 times
by 1× TBS and 1 % Tween 20 (pH 7.4) as washing buf-
fer. It was followed by incubation in 1/1000 dillution of
Rabbit Anti Sheep Ig Peroxidase conjugated (SPH 224,
Avicina) for 1 h at 37 °C and washed again as men-
tioned. 3,3′-diaminobenzidine tetrahydrochloride (DAB)
was used as substrate for visualization of the subjected
protein bands in presence of hydrogen peroxide.
Fig. 1 a Colony PCR with M13 primers, Romiplostim fragment (1000 bp) is shown; b The plasmid containing inserted fragment (Romiplostim)
treated by HindIII restriction enzyme, Romiplostim fragment is indicated
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Purification of romiplostim recombinant protein
Lysing the inclusion bodies
The cultured bacteria was centrifuged and the resulted
pellet was washed in ice cold STE (0.1 M NaCl, 10 mM
Tris. Cl, 1 mM EDTA) pH 8.0. The ice cold solution
(50 mM Tris. Cl, 10 % Sucrose) pH 8.0, 2 ml of fresh lyso-
zyme (10 mg/ml in 10 mM Tris. Cl [pH 8]), 0.25 M EDTA
and PMSF was added to the washed pellet as lysis buffer,
mixed vigorously and inverted several times on the ice
surface. Cells were hold at −20 °C for 1 h. Afterward cells
were lysed completely by sonication with 40 cycles: 30s
on, 15 s off, at 0 °C; amplitude: 10 (MSE Soniprep 150
Plus). The lysate was centrifuged at 4 °C, 4000 rpm for
30 min. and the supernatant was discarded.
Washing and solubilization
The pellet was re-suspended with 6 ml wash buffer (2 M
Urea, 100 mM Tris. Cl [pH 7.0], 5 mM EDTA, 2 %(w/v)
Triton X100) per gram of wet weight cells and the pro-
cedure was repeated for three times. After that the pel-
lete was re-suspended in wash buffer lacking Triton X-
100 and Urea. After each washing step, the supernatant
was centrifuged at 4 °C, 4000 rpm for 30 min. The pellet
was re-suspended in 10 times solubilization buffer (8 M
Urea, 50 mM Tris, 8 mM DTT [pH 10]) for 1 h in the
shaker at room temperature [13].
Refolding
This stage was down according to US patent (6835809 B1.
In brief. the solubilized mixture was diluted slowly 20 times
into Tris 50 mM, Arginine 160 mM, Urea [1-2 M] and
Cystein [3-5 mM], pH 8.5. The mixture was stirred at 4 °C,
overnight. The solution was concentrated about 10 fold
with Amicon Ultra-15 Centifugal Filter (cut-off: 50 kDa).
Afterward it was diluted three folds in Tris 10 mM and
Urea 1.5 M, pH 9. The refolding step was done.
Affinity chromatography
The recombinant Romiplostim mixture was passed over
Protein A Sepharoose (SIGMA-ALDRICH) by Sodium
Phosphate buffer 20 mM (pH 7.0) to result in Fc region
binding. The Fc mediated bonded peptibody was eluted
by sodium acetate buffer 20 mM (pH 4.0). The purified
Romiplostim was run in to 12 % SDS-PAGE electro-
phoresis and immunoblotting was carried out. Bio-Rad
Protein Assay was performed.
Fig. 2 a Double digestion of the Romiplostim plasmid with BamHI/NdeI, Romiplostim fragment is identified; b Double digestion of pET-22b(+)
with BamHI/NdeI
Fig. 3 Colony PCR with T7 primers, Romiplostim fragment is indicated
Fig. 4 SDS-PAGE analysis of 2 h, 4 h, 6 h and overnight induced
with 1 mM IPTG beside overnight uninduced of recombinant
Romiplostim. High expression of Romiplostim inclusion body in
uninduced recombinant Romiplostim was observed
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Biological activity
Twenty normal female BALB/c mice (7–9 weeks of age)
were divided into control and case groups. Recombinant
Romiplostim (50 μg/kg) and normal saline (0.2 mL/mice)
were subcutaneously injected into case and control
groups, respectively, on day 0. The whole blood factors
were evaluated by hematology analyzer (Sysmex KX-21)
on days 0, 4, 7, 17 through preorbital sinus sampling.
Results and discussion
Construction of expression vector
There are many hosts used for the production of recom-
binant protein but the preferred choice is E. coli due to its
easier culture, short life cycle, well known genetics and
easy genetic manipulation. Production of recombinant
protein in E. coli is less costly than using other hosts and
the handling is also easier [14]. Therefore the synthetic
fragment was successfully transformed into DH5α E. coli
competent cells. Colony PCR with M13 primers beside
HindIII restriction enzyme assay, showed expected bands
at 1000 and 800 bp, respectively (Fig. 1a, b). In this study
insoluble form of Romiplostim as inclusion body was
assessed and pET22b(+) vector was used. This vector har-
bor secretion signal and 6xHis fusion sequences, which
were omitted from the vector and 6xHis sequences has
situated after the stop codon. Amplified fragment and
pET-22b(+) plasmid vector were purified and digested
with BamHI/NdeI. The fragments were gel purified and
subjected to ligation (Fig. 2a, b). After transformation into
Fig. 5 Immunoblottig pattern comparison of expressed recombinant
protein in induced and uninduced cells; lane 1: 6 h induced cells by
IPTG (1 mM), lane 2: Overnight induced cells by IPTG (1 mM), lane 3:
Overnight uninduced cells and lane 4: Overnight BL21 (DE3) without
any plasmid (nonspecific band is seen)
Fig. 6 Immunoblottig pattern of the purified recombinant Romiplostim.
Lane 1: Monomeric structure of the recombinant Romiplostim (30 kDa),
disulfide bonds are reduced with 2ME; Lane 2: Dimeric structure of
recombinant Romiplostim (60 kDa), 2ME was omitted of the loading
buffer. The findings showed accurate molecules were produced
and purified
Fig. 7 Comparison of platelet counts (103/μl) between recombinant
Romiplostim Injected Group and Control Group on days 0, 4, 7 and
17. On day 0 Recombinant Romiplostim (50 μg/kg) and normal
saline (0.2 mL/mice) were subcutaneously injected into case and
control groups, respectively. Mean platelet counts were assayed on
days 0, 4, 7, 17 through preorbital sinus sampling. As it is shown in
the recombinant Romiplostim treated group, platelet value has
increased nearly more than 2 folds to the control group on day 4,
and it returned to day 0 level on day 17. Error bar (95 % CI): Platelet
counts in 10 BALB/c mice in each case and control group
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BL21 (DE3), colony PCR with T7 universal primers was
carried out for the retrieved correct colons. The expected
size was about 1000 bp (Fig. 3).
Expression analysis
Expressed recombinant protein of induced and unin-
duced cells, was compared (Fig. 4), high expression of
Romiplostim inclusion body in the absence of IPTG was
a great cost effective point. In Western blot, Fcγ carrier
domain of the recombinant protein was reactive to goat
anti-human IgG Fcγ as a primary antibody, followed by
peroxidase conjugated rabbit anti-sheep IgG. Sharp and
distinct Romiplostim recombinant protein band in
30 kDa was in accordance with the calculated molecular
weight of Romiplostim single strand (Fig. 5).
Refolding and purification of recombinant romiplostim
In contrast to US patent (6835809 B1) which researchers
recruited two step Ion Exchange chromatography, in the
present study we used protein A affinity chromatography
system to reduce purification stages. In order to perceive
refolded and purified recombinant Romiplostim by protein
A affinity chromatography, immunoblotting was per-
formed (Fig. 6); 2ME was omitted of the loading buffer, so
60 kDa protein band was shown which was related to the
quaternary structure of this protein. Besides, 30 kDa pro-
tein band in the form of denaturated protein was observed
(loading buffer contained 2ME). These findings showed ac-
curate molecules were produced and purified.
Biological activity
Our data indicated that platelet value has increased ap-
proximately more than 2 fold in the recombinant Romi-
plostim treated group to the control group on day 4, and
it returned to day 0 level on day 7 and 17 (Fig. 7). Other
blood factors remained unchanged on days 0, 4, 7 and
17 (it is showed in attach file). As it was expected, plate-
let increase was transient and returned to the normal
range after several days, it was proved in the previous
study too [15]. So weekly injection in keeping platelet
count is required. Laboratory scale production of Romi-
plostim may be followed by scale up of its production to
response the chronic ITP patients’ demands.
Conclusion
In this study, we evaluated a new approach for expression
and purification of this recently introduced thrombopoie-
tin receptor agonist drug. Using pET vector, we produced
recombinant Romiplostim in E. coli, and showed proper
in-vivo bioactivity. However, further characterization of
Romiplostim e.g. by cicular dichroism is needed. In
addition, dose dependence compression of the bioactivity
of this recombinant protein with Romiplostim (N-Plate)
which is in clinical use, is required.
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